You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 54 No. 10, October 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Amyotrophic lateral sclerosis. Insights from genetics

R. H. Brown Jr
Day Neuromuscular Research Laboratory, Massachusetts General Hospital-East, Charlestown, USA. Brown@helix.mgh.harvard.edu

Amyotrophic lateral sclerosis (ALS) is among the most dire neurological diseases. The essential clinical feature of the disorder is relentless, lethal paralysis, usually beginning in midadult years. The disease is caused by a slow, progressive loss of motor neurons in the brain and spinal cord. It usually begins focally and then spreads. In most cases, there is concurrent involvement of corticospinal (upper) and spinal (lower) motor neurons, although in some instances the spinal motor neuron features predominate. Involvement of the spinal motor neurons produces muscle denervation of the affected muscles and fasciculations, followed by muscle atrophy. When corticospinal motor neurons degenerate, the weakness is accompanied by spasticity. The mean age at onset of ALS is 55 years; the mean duration is about 4 years. The incidence of new cases is approximately 1 per 100,000 population. The total number of cases is about 5 per 100,000 population. In the United States, it is estimated that there are 20,000 to 30,000 cases. About 10% of cases are inherited as an autosomal dominant trait; familial and sporadic ALS are clinically indistinguishable.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lifetime occupation, education, smoking, and risk of ALS
Sutedja et al.
Neurology 2007;69:1508-1514.
ABSTRACT | FULL TEXT  

Mitochondrial nitric oxide in the signaling of cell integrated responses
Carreras and Poderoso
Am. J. Physiol. Cell Physiol. 2007;292:C1569-C1580.
ABSTRACT | FULL TEXT  

Translational Control of Glial Glutamate Transporter EAAT2 Expression
Tian et al.
J. Biol. Chem. 2007;282:1727-1737.
ABSTRACT | FULL TEXT  

The Association Between H63D Mutations in HFE and Amyotrophic Lateral Sclerosis in a Dutch Population
Sutedja et al.
Arch Neurol 2007;64:63-67.
ABSTRACT | FULL TEXT  

S-nitrosothiol depletion in amyotrophic lateral sclerosis
Schonhoff et al.
Proc. Natl. Acad. Sci. USA 2006;103:2404-2409.
ABSTRACT | FULL TEXT  

Mitochondria-associated apoptotic signalling in denervated rat skeletal muscle
Siu and Alway
J. Physiol. 2005;565:309-323.
ABSTRACT | FULL TEXT  

Friedreich ataxia: the oxidative stress paradox
Seznec et al.
Hum Mol Genet 2005;14:463-474.
ABSTRACT | FULL TEXT  

Excess incidence of ALS in young Gulf War veterans
Haley
Neurology 2003;61:750-756.
ABSTRACT | FULL TEXT  

Accelerated S-Nitrosothiol Breakdown by Amyotrophic Lateral Sclerosis Mutant Copper,Zinc-Superoxide Dismutase
Johnson et al.
J. Biol. Chem. 2001;276:39872-39878.
ABSTRACT | FULL TEXT  

Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis
Hausdorff et al.
J. Appl. Physiol. 2000;88:2045-2053.
ABSTRACT | FULL TEXT  

Novel role of phosphorylation in Fe-S cluster stability revealed by phosphomimetic mutations at Ser-138 of iron regulatory protein 1
Brown et al.
Proc. Natl. Acad. Sci. USA 1998;95:15235-15240.
ABSTRACT | FULL TEXT  

Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models
Price et al.
Science 1998;282:1079-1083.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.